Revenio Group Corporation’s Board of Directors established an Audit Committee
Revenio Group Corporation, Stock Exchange Release May 10, 2019 at 14.00 (EET)
Revenio Group Corporation’s Board of Directors established an Audit Committee
Revenio Group Corporation's Board of Directors has made a decision to establish an Audit Committee.
In accordance with the charter of the Audit Committee, the Board elected the following members from among its members for the Committee: Pekka Tammela, Pekka Rönkä and Ann-Christine Sundell.
The Audit Committee is responsible for:
- monitoring the statutory auditing of the financial statements and consolidated financial statements as well as the reporting process and ensure their accuracy
- supervising the financial reporting process
- reviewing the effectiveness of Revenio Group Corporation's internal control and risk management systems, the Group's risks, and the quality and scope of risk management
- approving the internal audit guidelines and reviewing the internal audit plans and reports
- reviewing the description of the main features of the internal control and risk management systems in relation to the financial reporting process, which is included in the company's Corporate Governance Statement
- evaluating the independence and work of the statutory auditor and proposing a resolution on the election and fee of the auditor
- evaluating compliance with laws, regulations, and company policies and monitoring significant litigations of Group companies, and
- executing any other duties bestowed upon it by the Board.
Revenio Group Corporation
For further information, please contact:
CEO Timo Hildén
Tel. +358 40 580 4774
www.ventica.fi
DISTRIBUTION:
Nasdaq Helsinki
Financial Supervisory Authority
Principal media
The Revenio Group in brief
Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology.
The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy. Revenio’s core business is to develop and commercialize effective and easily adopted devices to assist in the diagnostics of glaucoma and its monitoring during treatment.
Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio’s technology is on the early detection of glaucoma, skin cancer and asthma, and the monitoring of these during the treatment process.
In 2018, the Revenio Group's net sales totaled EUR 30.7 million, with its operating margin standing at 33.3%. Revenio Group Corporation is listed on Nasdaq Helsinki.